Vildagliptin 598 Smiles: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)CC)C(=O)COC(=O)CC

Smiles: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)CC)C(=O)COC(=O)CC

This is consistent with previous reports indicating that Sotrastaurin inhibits ERK1/2 phosphorylation in GNAQ mutant cell lines

71(5):1573-83

Sagimid monohydrate

7-dihydroxy-2-(4-hydroxyphenyl)-3-{[(2S

Vildagliptin 598 Smiles: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)CC)C(=O)COC(=O)CCVildagliptin (also known as LAF237 and Zomelis) is an oral anti hyperglycemic agent (anti diabetic drug) of the new dipeptidyl peptidase 4 (DPP 4) inhibitor class of drugs. Vildagliptin inhibits the inactivation of GLP 1 and GIP by DPP 4, allowing GLP 1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas. Vildagliptin has been shown to reduce